A Phase 1, Open Label Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors
Latest Information Update: 07 Jan 2022
At a glance
- Drugs ASP-8374 (Primary)
- Indications Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Astellas Pharma
Most Recent Events
- 09 Jul 2020 Status changed from active, no longer recruiting to completed.
- 05 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 21 Aug 2019 Status changed from not yet recruiting to recruiting.